Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 7, 2019

Primary Completion Date

August 1, 2028

Study Completion Date

August 1, 2028

Conditions
Diabetes Mellitus, Type 1
Interventions
BIOLOGICAL

Allogenic Human Islet Cells

islet cells transplanted into the portal vein in the liver

DRUG

Gastrin 17

"Gastrin-17 (or GAST-17) - a gut hormone injected under the skin twice daily for 30 days soon after islet transplant and again 6 months later.~Also, anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets."

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

University of California, Los Angeles

OTHER

lead

City of Hope Medical Center

OTHER